Physician
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $125.54M by Medicaid between Jan 2018 and Dec 2024, across 587 billing codes. Its largest line is 99284, emergency room visit (serious) — 8.7% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
JAMAICA, NY 11432
JAMAICA, NY 11432
33aNPI1801803903assigned 08/02/2006
33bProvider typeInternal Medicine Physician
28Total paid$125.54M
24GClaims3,041,842
24DCodes billed587
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#6 of 6,049
Median peer was paid$11K
This provider vs. median11,098×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,290 | $568K | |
| 2019 | 206,683 | $7.07M | |
| 2020 | 483,138 | $20.47M | |
| 2021 | 705,688 | $28.72M | |
| 2022 | 665,213 | $29.20M | |
| 2023 | 481,010 | $20.93M | |
| 2024incomplete | 435,820 | $18.59M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.7% | 72,067 | 66,174 | $10.98M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.1% | 72,114 | 66,751 | $10.18M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.9% | 131,062 | 111,250 | $9.92M |
| 36415 | Collection of venous blood by venipuncture | 5.7% | 382,964 | 146,784 | $7.11M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.4% | 90,182 | 28,419 | $5.55M |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | 4.3% | 9,201 | 7,780 | $5.45M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.2% | 65,136 | 57,732 | $5.25M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 3.1% | 29,701 | 19,492 | $3.90M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.9% | 57,757 | 51,572 | $3.58M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 19,212 | 18,017 | $3.05M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.2% | 14,866 | 13,947 | $2.82M |
| G0378 | Hospital observation service, per hour | 2.0% | 2,198 | 2,135 | $2.46M |
575 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.8% | 33,929 | $2.28M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 13,313 | $2.24M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.7% | 31,603 | $2.12M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.2% | 26,952 | $1.45M |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | 1.1% | 1,863 | $1.35M |
| 90834 | Psychotherapy session, about 45 minutes | 1.1% | 7,684 | $1.34M |
| H0040 | Assertive community treatment program, per diem | <1% | 617 | $1.11M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 24,504 | $1.04M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 28,219 | $936K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 46,468 | $860K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,532 | $854K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 12,609 | $828K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 7,444 | $796K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 36,703 | $787K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 11,967 | $780K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 83,403 | $769K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 3,970 | $766K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,948 | $738K |
| H0037 | Community psychiatric supportive treatment program, per diem | <1% | 636 | $728K |
| 81408 | <1% | 484 | $684K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,384 | $664K |
| D0999 | Unspecified diagnostic procedure, by report | <1% | 3,968 | $632K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 4,307 | $629K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,895 | $628K |
| S9485 | Crisis intervention mental health services, per diem | <1% | 471 | $615K |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 4,604 | $598K |
| 99442 | <1% | 11,846 | $553K | |
| 59025 | Fetal non-stress test | <1% | 4,717 | $520K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 715 | $487K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,159 | $475K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,218 | $468K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 35,158 | $467K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,246 | $457K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 983 | $453K |
| 99201 | <1% | 4,964 | $446K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 3,132 | $438K |
| 99443 | <1% | 5,664 | $428K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 4,138 | $423K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 20,067 | $413K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 12,367 | $405K |
| 80061 | Lipid panel | <1% | 41,693 | $399K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,713 | $382K |
| 80053 | Comprehensive metabolic panel | <1% | 34,952 | $370K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 490 | $361K |
| 85027 | <1% | 123,196 | $355K | |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 369 | $351K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,972 | $341K |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 2,387 | $330K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 4,061 | $325K |
| 86480 | <1% | 5,542 | $309K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 26,463 | $302K |
| 80076 | <1% | 45,838 | $302K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,482 | $300K |
| 99441 | <1% | 11,704 | $288K | |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 3,253 | $287K |
| 90461 | <1% | 16,496 | $286K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 42,449 | $281K |
| 76641 | <1% | 2,687 | $279K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,748 | $276K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,701 | $259K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 10,311 | $250K |
| 90677 | <1% | 2,348 | $243K | |
| 87536 | <1% | 2,624 | $240K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 21,746 | $235K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 29,776 | $228K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 352 | $221K |
| 90750 | <1% | 2,875 | $220K | |
| 0002A | <1% | 6,619 | $203K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 6,375 | $200K |
| 93970 | <1% | 807 | $200K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 22,658 | $199K |
| 92134 | <1% | 5,296 | $193K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,915 | $193K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 961 | $191K |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 2,547 | $188K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,036 | $186K |
| 86703 | <1% | 14,462 | $185K | |
| 0001A | <1% | 6,734 | $185K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,573 | $183K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,528 | $180K |
| 99205 | Prolong outpt/office vis | <1% | 979 | $179K |
| 67228 | <1% | 704 | $179K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,316 | $178K |
| 70486 | <1% | 1,506 | $177K | |
| 99381 | <1% | 2,722 | $173K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 796 | $171K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 730 | $170K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,158 | $169K |
| 83655 | <1% | 14,476 | $167K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,800 | $166K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,268 | $165K |
| 86360 | <1% | 3,446 | $164K | |
| 86850 | <1% | 8,563 | $158K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 99 | $151K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,393 | $151K |
| 76830 | Ultrasound, transvaginal | <1% | 2,428 | $149K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 21,229 | $142K |
| 90715 | <1% | 6,243 | $142K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 10,921 | $142K |
| 92250 | <1% | 3,976 | $140K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 1,951 | $134K |
| 0004A | <1% | 3,639 | $134K | |
| 76818 | <1% | 1,211 | $133K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,499 | $132K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,050 | $131K |
| 90651 | <1% | 2,551 | $129K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,847 | $129K |
| 97802 | <1% | 3,447 | $127K | |
| 86359 | <1% | 3,456 | $127K | |
| 71250 | <1% | 717 | $125K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,073 | $121K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 721 | $112K |
| 86769 | <1% | 3,583 | $112K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 3,153 | $109K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,246 | $107K |
| 81329 | <1% | 862 | $105K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 355 | $105K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,620 | $105K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 854 | $104K |
| 81161 | <1% | 503 | $104K | |
| 77065 | Tomosynthesis, mammo | <1% | 894 | $101K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 397 | $100K |
| 86901 | <1% | 8,675 | $98K | |
| 92083 | <1% | 1,803 | $95K | |
| 96156 | <1% | 957 | $94K | |
| 88142 | <1% | 3,900 | $89K | |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 2,708 | $89K |
| 82805 | <1% | 11,226 | $87K | |
| 84703 | <1% | 21,374 | $87K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 87 | $80K |
| 87631 | <1% | 2,481 | $78K | |
| 83880 | <1% | 5,275 | $78K | |
| 86780 | <1% | 7,697 | $77K | |
| 86900 | <1% | 8,661 | $77K | |
| 90674 | <1% | 4,463 | $76K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 84 | $75K |
| 87486 | <1% | 4,162 | $74K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,925 | $72K |
| 12001 | <1% | 279 | $72K | |
| 97124 | <1% | 2,633 | $70K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,925 | $68K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 338 | $68K |
| 90686 | <1% | 9,756 | $66K | |
| 76770 | <1% | 397 | $66K | |
| 96127 | <1% | 18,109 | $66K | |
| 84439 | <1% | 8,957 | $65K | |
| 90746 | <1% | 1,222 | $65K | |
| 19083 | <1% | 76 | $65K | |
| 82728 | <1% | 6,302 | $63K | |
| 99051 | <1% | 5,711 | $63K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,108 | $63K |
| 86803 | <1% | 6,461 | $62K | |
| 96161 | <1% | 7,460 | $60K | |
| 92015 | Determination of refractive state | <1% | 2,466 | $59K |
| 92133 | <1% | 1,587 | $59K | |
| 82607 | <1% | 5,493 | $59K | |
| 73630 | <1% | 3,231 | $55K | |
| 73564 | <1% | 2,318 | $54K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 266 | $54K |
| 87581 | <1% | 4,163 | $53K | |
| 96367 | <1% | 2,176 | $53K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 693 | $52K |
| 97010 | <1% | 6,667 | $52K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 16,017 | $51K |
| 82948 | <1% | 24,341 | $50K | |
| 99188 | <1% | 2,980 | $49K | |
| 90670 | <1% | 4,668 | $49K | |
| 76801 | <1% | 387 | $49K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,117 | $49K |
| H0049 | Alcohol and/or drug screening | <1% | 694 | $48K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,571 | $47K |
| 76536 | <1% | 451 | $47K | |
| 77066 | Tomosynthesis, mammo | <1% | 326 | $46K |
| 77062 | <1% | 305 | $46K | |
| 72100 | <1% | 2,145 | $44K | |
| 81243 | <1% | 988 | $44K | |
| 85610 | <1% | 12,355 | $44K | |
| 97014 | <1% | 3,201 | $44K | |
| 90698 | <1% | 5,643 | $42K | |
| 90732 | <1% | 479 | $41K | |
| 83020 | <1% | 3,532 | $40K | |
| 93971 | <1% | 607 | $39K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 6,079 | $38K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 294 | $37K |
| 87340 | <1% | 4,992 | $37K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 219 | $37K |
| 0003A | <1% | 917 | $37K | |
| 82951 | <1% | 3,280 | $37K | |
| 77061 | <1% | 292 | $36K | |
| 81001 | <1% | 26,931 | $36K | |
| 0072A | <1% | 834 | $35K | |
| 73030 | <1% | 2,028 | $35K | |
| 81003 | <1% | 17,723 | $34K | |
| 83550 | <1% | 5,536 | $34K | |
| D1206 | Topical application of fluoride varnish | <1% | 5,680 | $33K |
| 90680 | <1% | 4,343 | $33K | |
| 92567 | <1% | 1,084 | $32K | |
| 87535 | <1% | 936 | $32K | |
| 86706 | <1% | 3,787 | $31K | |
| 86762 | <1% | 2,430 | $31K | |
| 0071A | <1% | 799 | $31K | |
| 93017 | <1% | 556 | $31K | |
| 84153 | <1% | 1,937 | $31K | |
| 84702 | <1% | 11,945 | $30K | |
| S9083 | Global fee urgent care centers | <1% | 278 | $30K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 64 | $29K |
| 92557 | <1% | 811 | $29K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 35,607 | $29K |
| 73610 | <1% | 1,821 | $29K | |
| 83540 | <1% | 6,080 | $27K | |
| 86765 | <1% | 2,390 | $27K | |
| 0124A | <1% | 665 | $26K | |
| 82043 | <1% | 5,780 | $26K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 416 | $26K |
| 90744 | <1% | 3,296 | $25K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 129 | $24K |
| 83970 | <1% | 765 | $23K | |
| 96167 | <1% | 924 | $23K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 847 | $23K |
| 12011 | <1% | 73 | $23K | |
| 86704 | <1% | 2,370 | $23K | |
| 90734 | <1% | 839 | $21K | |
| 73130 | <1% | 1,716 | $21K | |
| 80320 | <1% | 13,447 | $20K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 49 | $20K |
| 70498 | <1% | 107 | $19K | |
| 90633 | <1% | 2,647 | $18K | |
| 73110 | <1% | 1,168 | $18K | |
| 82105 | <1% | 1,406 | $18K | |
| 86357 | <1% | 565 | $18K | |
| 86355 | <1% | 565 | $18K | |
| 10060 | <1% | 90 | $17K | |
| 77336 | <1% | 85 | $17K | |
| 3074F | <1% | 31,509 | $16K | |
| 90707 | <1% | 1,324 | $16K | |
| 90716 | <1% | 1,388 | $16K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 4,332 | $16K |
| 84484 | <1% | 16,301 | $15K | |
| 90662 | <1% | 796 | $15K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,225 | $15K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,705 | $15K |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 170 | $15K |
| 92240 | <1% | 95 | $14K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 514 | $14K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 12 | $14K |
| 73502 | <1% | 660 | $14K | |
| 77412 | <1% | 249 | $14K | |
| 97597 | <1% | 47 | $14K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 10,638 | $14K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 2,263 | $13K |
| 91320 | <1% | 350 | $13K | |
| 92579 | <1% | 222 | $13K | |
| 90620 | <1% | 580 | $13K | |
| 88141 | <1% | 545 | $13K | |
| 92550 | <1% | 397 | $13K | |
| 73560 | <1% | 614 | $13K | |
| 87081 | <1% | 3,596 | $13K | |
| D0120 | Dental checkup, returning patient | <1% | 1,421 | $12K |
| 83735 | <1% | 16,830 | $12K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 81 | $12K |
| 90480 | <1% | 396 | $12K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 692 | $12K |
| 76820 | <1% | 247 | $12K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 69 | $12K |
| 86141 | <1% | 2,812 | $11K | |
| 85730 | <1% | 6,149 | $11K | |
| 85007 | <1% | 10,094 | $11K | |
| 77080 | <1% | 462 | $11K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 906 | $11K |
| 83516 | <1% | 953 | $11K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 107 | $10K |
| D1120 | Dental cleaning, child | <1% | 1,272 | $10K |
| 82248 | <1% | 2,460 | $10K | |
| 82274 | <1% | 1,060 | $10K | |
| D1110 | Prophylaxis - adult | <1% | 587 | $10K |
| 73700 | <1% | 42 | $9K | |
| 86787 | <1% | 892 | $9K | |
| 87186 | <1% | 2,486 | $9K | |
| 88312 | <1% | 142 | $9K | |
| 83001 | <1% | 508 | $9K | |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | <1% | 72 | $9K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,532 | $9K |
| 90656 | <1% | 966 | $8K | |
| 86038 | <1% | 1,061 | $8K | |
| D0140 | Limited oral evaluation - problem focused | <1% | 655 | $8K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 312 | $8K |
| 86735 | <1% | 709 | $8K | |
| 73590 | <1% | 825 | $8K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,483 | $8K |
| 76870 | <1% | 129 | $8K | |
| 88307 | <1% | 115 | $8K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 823 | $8K |
| 90661 | <1% | 551 | $7K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 251 | $7K |
| 92201 | <1% | 244 | $7K | |
| 74019 | <1% | 357 | $7K | |
| 93225 | <1% | 107 | $7K | |
| 73090 | <1% | 631 | $7K | |
| 84403 | <1% | 279 | $7K | |
| 99383 | <1% | 246 | $7K | |
| 84146 | <1% | 376 | $7K | |
| 81025 | <1% | 2,154 | $7K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 48 | $7K |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 144 | $6K |
| 96168 | <1% | 187 | $6K | |
| 74022 | <1% | 354 | $6K | |
| 82803 | <1% | 3,415 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,086 | $6K |
| 82247 | <1% | 1,385 | $6K | |
| 96376 | <1% | 2,227 | $6K | |
| 72131 | <1% | 42 | $6K | |
| 82952 | <1% | 783 | $6K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 476 | $6K |
| 86160 | <1% | 387 | $6K | |
| 83690 | <1% | 10,865 | $6K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 54 | $5K |
| 93226 | <1% | 107 | $5K | |
| 51798 | <1% | 69 | $5K | |
| 83615 | <1% | 1,420 | $5K | |
| 90694 | <1% | 290 | $5K | |
| 87338 | <1% | 499 | $5K | |
| 90710 | <1% | 626 | $5K | |
| 81002 | <1% | 1,356 | $5K | |
| 74018 | <1% | 321 | $5K | |
| 70496 | <1% | 41 | $5K | |
| 90653 | <1% | 186 | $5K | |
| 82677 | <1% | 189 | $5K | |
| 85045 | <1% | 1,789 | $4K | |
| 73140 | <1% | 257 | $4K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 31 | $4K |
| 85651 | <1% | 1,892 | $4K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 741 | $4K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 975 | $4K |
| 99384 | <1% | 78 | $4K | |
| 12002 | <1% | 16 | $4K | |
| 82550 | <1% | 1,558 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,052 | $4K |
| 96368 | <1% | 241 | $4K | |
| D0274 | Bitewings - four radiographic images | <1% | 729 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,128 | $4K |
| 86235 | <1% | 110 | $4K | |
| 92227 | <1% | 233 | $4K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 124 | $4K |
| 83002 | <1% | 224 | $4K | |
| 87040 | <1% | 2,920 | $4K | |
| 94060 | <1% | 64 | $4K | |
| 97161 | <1% | 40 | $4K | |
| 97162 | <1% | 49 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,764 | $4K |
| 90696 | <1% | 575 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 648 | $4K |
| 86225 | <1% | 413 | $4K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 13 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,009 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,880 | $3K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 681 | $3K |
| 85379 | <1% | 2,834 | $3K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 814 | $3K |
| 97165 | <1% | 34 | $3K | |
| 69210 | <1% | 101 | $3K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 1,414 | $3K |
| 70490 | <1% | 15 | $3K | |
| 84550 | <1% | 1,132 | $3K | |
| 94729 | <1% | 57 | $3K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,760 | $3K |
| 72040 | <1% | 129 | $3K | |
| 86140 | <1% | 718 | $3K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 231 | $3K |
| 97803 | <1% | 83 | $3K | |
| 84704 | <1% | 189 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,334 | $3K |
| 3078F | <1% | 30,939 | $2K | |
| 73080 | <1% | 192 | $2K | |
| 86336 | <1% | 189 | $2K | |
| 80165 | <1% | 472 | $2K | |
| 93247 | <1% | 12 | $2K | |
| 84154 | <1% | 134 | $2K | |
| 80321 | <1% | 151 | $2K | |
| 86592 | <1% | 497 | $2K | |
| 82746 | <1% | 226 | $2K | |
| 94727 | <1% | 57 | $2K | |
| 0012A | <1% | 109 | $2K | |
| 90672 | <1% | 534 | $2K | |
| 86255 | <1% | 253 | $2K | |
| 36430 | <1% | 13 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,966 | $2K |
| 86003 | <1% | 50 | $2K | |
| 96160 | <1% | 159 | $2K | |
| 90474 | <1% | 397 | $2K | |
| 0031A | <1% | 46 | $2K | |
| 84100 | <1% | 895 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,404 | $2K |
| D9990 | <1% | 172 | $2K | |
| 99402 | <1% | 24 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,746 | $2K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 29 | $2K |
| 96417 | <1% | 19 | $2K | |
| 96154 | <1% | 30 | $2K | |
| 0011A | <1% | 124 | $2K | |
| 99382 | <1% | 28 | $2K | |
| 92202 | <1% | 81 | $2K | |
| J3471 | Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) | <1% | 43 | $2K |
| 92582 | <1% | 16 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 410 | $1K |
| 83605 | <1% | 1,891 | $1K | |
| 76642 | <1% | 12 | $1K | |
| 82330 | <1% | 1,875 | $1K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 15 | $1K |
| 84402 | <1% | 54 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,637 | $1K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 5,511 | $1K |
| H2027 | Psychoeducational service, per 15 minutes | <1% | 23 | $1K |
| D0272 | Bitewings - two radiographic images | <1% | 420 | $1K |
| 84155 | <1% | 377 | $1K | |
| 1159F | <1% | 10,022 | $1K | |
| 73060 | <1% | 133 | $1K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 511 | $1K |
| 86593 | <1% | 356 | $1K | |
| 87517 | <1% | 27 | $1K | |
| 80051 | <1% | 168 | $1K | |
| 15853 | <1% | 12 | $1K | |
| 82985 | <1% | 82 | $1K | |
| 73070 | <1% | 67 | $1K | |
| 85384 | <1% | 261 | $1K | |
| 82570 | <1% | 288 | $1K | |
| 11721 | <1% | 25 | $1K | |
| 73600 | <1% | 75 | $984.57 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 3,135 | $973.33 |
| 0074A | <1% | 28 | $954.70 | |
| 90685 | <1% | 336 | $948.98 | |
| 86430 | <1% | 212 | $938.89 | |
| 86376 | <1% | 72 | $938.55 | |
| 84156 | <1% | 344 | $920.90 | |
| 82397 | <1% | 736 | $903.57 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 25 | $857.28 |
| 82378 | <1% | 58 | $848.62 | |
| 73562 | <1% | 140 | $844.61 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,620 | $828.40 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 28 | $792.06 |
| 82785 | <1% | 55 | $788.75 | |
| 87420 | <1% | 446 | $783.39 | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 12 | $770.79 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,062 | $750.40 |
| 73120 | <1% | 30 | $747.85 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 188 | $669.27 |
| 0154A | <1% | 18 | $659.45 | |
| 99225 | <1% | 12 | $659.25 | |
| 87593 | <1% | 14 | $638.99 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 597 | $638.03 |
| 73552 | <1% | 40 | $614.63 | |
| 3079F | <1% | 14,794 | $600.01 | |
| 92082 | <1% | 12 | $575.22 | |
| 93246 | <1% | 12 | $568.44 | |
| 88342 | <1% | 15 | $560.34 | |
| 82977 | <1% | 100 | $559.32 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,697 | $559.02 |
| 83718 | <1% | 250 | $555.09 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 145 | $551.34 |
| 86258 | <1% | 30 | $548.78 | |
| 72190 | <1% | 52 | $543.08 | |
| 0081A | <1% | 13 | $539.45 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,764 | $531.51 |
| 88304 | <1% | 24 | $530.22 | |
| 92551 | <1% | 1,264 | $522.05 | |
| 86334 | <1% | 30 | $520.37 | |
| 98960 | <1% | 20 | $515.02 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,530 | $487.46 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 43 | $463.08 |
| 84478 | <1% | 250 | $443.72 | |
| 73620 | <1% | 18 | $440.56 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,687 | $438.23 |
| G0008 | Administration of influenza virus vaccine | <1% | 575 | $433.68 |
| 82465 | <1% | 340 | $423.03 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 372 | $417.69 |
| 86800 | <1% | 28 | $415.25 | |
| 86708 | <1% | 38 | $398.28 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 69 | $393.15 |
| 87521 | Neg quan hep c or qual rna | <1% | 16 | $356.68 |
| 82947 | <1% | 235 | $346.82 | |
| V2632 | Posterior chamber intraocular lens | <1% | 14 | $323.37 |
| 82670 | <1% | 13 | $313.00 | |
| 80047 | <1% | 38 | $308.38 | |
| 99152 | <1% | 38 | $301.37 | |
| 86231 | <1% | 29 | $293.81 | |
| D1330 | <1% | 685 | $288.90 | |
| 71101 | <1% | 25 | $282.89 | |
| D0330 | Panoramic radiographic image | <1% | 47 | $271.16 |
| 93325 | <1% | 12 | $268.49 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 250 | $268.48 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 72 | $264.12 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 465 | $262.00 |
| 76857 | <1% | 14 | $261.00 | |
| 82565 | <1% | 58 | $257.29 | |
| 59425 | <1% | 14 | $250.75 | |
| 82962 | <1% | 248 | $244.89 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 177 | $237.71 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 109 | $233.87 |
| 72070 | <1% | 12 | $233.17 | |
| 84144 | <1% | 15 | $225.32 | |
| 80069 | <1% | 39 | $217.32 | |
| 90473 | <1% | 206 | $213.48 | |
| 97032 | <1% | 17 | $197.91 | |
| 71100 | <1% | 14 | $194.91 | |
| 90882 | <1% | 32 | $190.55 | |
| 97035 | <1% | 14 | $188.15 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 150 | $180.70 |
| D0191 | <1% | 565 | $162.38 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 262 | $142.16 |
| 83520 | <1% | 48 | $138.65 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 13 | $130.69 |
| 84165 | <1% | 15 | $119.34 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 113 | $114.12 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 312 | $110.59 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 55 | $109.94 |
| 87205 | <1% | 119 | $109.42 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 66 | $105.27 |
| 93018 | <1% | 13 | $105.18 | |
| 72050 | <1% | 12 | $97.34 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,461 | $93.35 |
| D2330 | <1% | 16 | $90.00 | |
| 82010 | <1% | 213 | $89.39 | |
| 90647 | <1% | 18 | $89.25 | |
| 90723 | <1% | 17 | $89.25 | |
| 83010 | <1% | 12 | $79.26 | |
| 90660 | <1% | 28 | $79.08 | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 15 | $77.60 |
| G0009 | Administration of pneumococcal vaccine | <1% | 12 | $71.35 |
| 94760 | <1% | 25 | $65.58 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 16 | $56.26 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 30 | $44.91 |
| 80178 | <1% | 13 | $39.98 | |
| 87070 | <1% | 14 | $38.62 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 68 | $38.33 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 37 | $37.11 |
| 82553 | <1% | 17 | $36.53 | |
| 84132 | <1% | 12 | $32.52 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 15 | $30.07 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 42 | $23.50 |
| 82150 | <1% | 12 | $21.49 | |
| 84436 | <1% | 13 | $15.52 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 41 | $11.54 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 28 | $10.97 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 68 | $10.46 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 18 | $5.75 |
| 85014 | <1% | 12 | $3.88 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 12 | $1.80 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 15 | $0.38 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 12 | $0.32 |
| S0028 | Injection, famotidine, 20 mg | <1% | 13 | $0.07 |
| 90623 | <1% | 12 | $0.02 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 0% | 207 | $0.00 |
| 3080F | 0% | 2,534 | $0.00 | |
| 3075F | 0% | 9,657 | $0.00 | |
| D0603 | 0% | 106 | $0.00 | |
| 1220F | 0% | 869 | $0.00 | |
| 99406 | 0% | 110 | $0.00 | |
| D0601 | 0% | 137 | $0.00 | |
| 3044F | 0% | 252 | $0.00 | |
| S9451 | Exercise classes, non-physician provider, per session | 0% | 84 | $0.00 |
| 99429 | 0% | 54 | $0.00 | |
| 3072F | 0% | 37 | $0.00 | |
| D0602 | 0% | 12 | $0.00 | |
| 0502F | 0% | 184 | $0.00 | |
| 99499 | 0% | 1,221 | $0.00 | |
| 1160F | 0% | 7,152 | $0.00 | |
| 3077F | 0% | 7,457 | $0.00 | |
| D0190 | 0% | 701 | $0.00 | |
| 99173 | 0% | 1,175 | $0.00 | |
| 99408 | 0% | 95 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 78 | $0.00 |
| G0445 | High intensity behavioral counseling to prevent sexually transmitted infection; face-to-face, individual, includes: education, skills training and guidance on how to change sexual behavior; performed semi-annually, 30 minutes | 0% | 90 | $0.00 |
| G0271 | Medical nutrition therapy, reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition, or treatment regimen (including additional hours needed for renal disease), group (2 or more individuals), each 30 minutes | 0% | 49 | $0.00 |
| 2022F | 0% | 25 | $0.00 | |
| 99080 | 0% | 2,067 | $0.00 | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.